Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Ribonuclease
60%
Glycosylation
44%
PD-L1
42%
Cancer Cell
42%
Immunity
35%
T Cell
26%
Phosphotransferase
23%
Kinase
23%
Receptor Tyrosine Kinase
21%
Immunosurveillance
19%
Nuclear Transport
19%
Methylation
19%
N-Linked Glycosylation
19%
Protein Characterization
19%
P53
19%
ROS1
19%
Immune Checkpoints
18%
Glycogen Synthase Kinase 3
17%
Anaplastic Lymphoma Kinase
15%
Cytotoxic T Cell
15%
Dynamics
14%
Tumor Progression
14%
Cell Activity
14%
Signal Transduction
14%
Epidermal Growth Factor
13%
Protein Interaction
13%
Binding Affinity
13%
Ribonuclease A
12%
Transcription
12%
Deglycosylation
12%
Cetuximab
11%
DNA Synthesis
11%
Tumor Immunity
11%
Angiogenin
11%
RNA
10%
Synapsin I
10%
Cell Death
10%
Sec61
10%
Tyrosine Kinase Inhibitor
10%
Cell Lysate
10%
Translocon
9%
Transport at the Cellular Level
9%
Tumor Initiation
9%
Erlotinib
9%
Programmed Cell Death 1
9%
Immune Evasion
9%
MCM7
9%
Methyltransferase
9%
Ephrin Receptor
9%
Keyphrases
Programmed Death-ligand 1 (PD-L1)
54%
Ribonuclease
49%
Tumor Immunity
41%
Mantle Cell Lymphoma
29%
Breast Tumor
20%
Epidermal Growth Factor Receptor
20%
Ribonuclease 7
19%
Hepatocellular Carcinoma
19%
PARP Inhibitor (PARPi)
19%
Ephrin Receptor A10
19%
Immunosuppression
19%
T Cell Activation
17%
Bruton Tyrosine Kinase Inhibitor
17%
Triple-negative Breast Cancer
16%
Cyclin-dependent Kinase 9 (CDK9)
15%
Breast Cancer
15%
Cancer Cells
15%
Anaplastic Lymphoma Kinase
14%
Membrane Receptors
13%
Lymphoma Cells
13%
Tumor Growth
13%
Receptor Biology
11%
Co-target
11%
Overcoming Resistance
11%
Putative Drug Targets
11%
Immune Escape
11%
Kinase Cascade
11%
Mouse Model
11%
Juxtacrine Signaling
10%
Phosphorylation
10%
Chemotherapy Resistance
10%
Triple-negative Breast Cancer Cells
10%
Therapeutic Response
10%
Sec61
9%
Translocon
9%
Digital Receptor
9%
Acid Metabolism
9%
Erlotinib
9%
MALT1
9%
Apoptosis
9%
Epidermal Growth Factor Receptor Family
9%
Lyn Kinase
9%
Uracil Phosphoribosyltransferase
9%
EGFR Signaling
9%
Bruton's Tyrosine Kinase
9%
Mesenchymal Transition
9%
Off-target Binding
9%
Protocol Optimization
9%
Aerobic Glycolysis
9%
H3K27me3
9%
Immunology and Microbiology
Programmed Death-Ligand 1
49%
Epstein Barr Virus
39%
Programmed Death 1 Ligand 1
31%
T Cell
25%
Immunotherapy
22%
Mouse Model
20%
Chimeric Antigen Receptor T-Cell
19%
Immunosuppression
19%
Lymphoma Cell
19%
Glycosylation
19%
Tumor Cell
18%
Cancer Cell
18%
Virus Reactivation
17%
Lytic Cycle
16%
Carcinoma Cell
14%
Innate Immune System
14%
Immunity
14%
Syngenic
13%
Chimeric Antigen Receptor T-Cell Therapy
13%
Binding Affinity
13%
Immunosurveillance
12%
Adaptive Immune System
11%
Monoclonal Antibody
11%
Signal Transduction
11%
Translocon
9%
Transport at the Cellular Level
9%
Sec61
9%
Protein Interaction
9%
Major Histocompatibility Complex
9%
Epidermal Growth Factor
9%
RNAI
9%
Anaplastic Lymphoma Kinase
9%
Dynamics
9%
Nucleocytoplasmic Transport
9%
Histone
9%
Genetic Transcription
9%
Cycline
9%
Immediate Early Protein BZLF1
9%
T Cell Activation
9%
Ferroptosis
9%
Receptor Occupancy
9%
Endoplasmic Reticulum
9%
Endoplasmic Reticulum Associated Degradation
9%
Epstein-Barr Virus Latent Membrane Protein 1
9%
Therapeutic Antibodies
9%
Cell Surface
9%
Immune Checkpoint Blockade
9%
Protein Complex
9%
Programmed Death 1 Receptor
8%
Promoter Region
8%
